Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

NCT02898116 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Carcinoma
NSCLC

Interventions

DRUG: Ensartinib
DRUG: Durvalumab

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]
[object Object]